Suppr超能文献

肿瘤进展过程中趋化因子及趋化因子受体表达与单核细胞-髓系来源抑制细胞的关联

Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression.

作者信息

Seo Eun-Hye, Namgung Ji Hyeon, Oh Chung-Sik, Kim Seong-Hyop, Lee Seung Hyun

机构信息

BK21 Plus, Department of Cellular and Molecular Medicine, Konkuk University School of Medicine, Seoul 05030, Korea.

Department of Microbiology, Konkuk University School of Medicine, Seoul 05030, Korea.

出版信息

Immune Netw. 2018 Jun 25;18(3):e23. doi: 10.4110/in.2018.18.e23. eCollection 2018 Jun.

Abstract

Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells that show increased expression in cancer patients; however, the molecular mechanisms underlying their generation and function are unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer (BC), the presence and relevance of monocytic (Mo)-MDSCs are unknown. Here, we report for the first time increased chemokine and chemokine receptor production by Mo-MDSCs in BC patients. A clear population of Mo-MDSCs with the typical cell surface phenotype (human leukocyte antigen-antigen D related [HLA-DR] CD11b CD33 CD14) increased significantly during disease progression. In addition, the chemokine receptor expression level on Mo-MDSCs in patients with invasive BC was the highest. Furthermore, different chemokine receptor expression patterns were noted in Mo-MDSCs between healthy controls (HC) and BC patients. Additionally, CD4 T cells proliferations were significantly decreased in the invasive BC groups compared with the HC group. However, the ductal carcinoma (DCIS) group had no significantly compared with the HC group. Our data suggest that monitoring chemokine and chemokine receptor production by Mo-MDSCs may represent a novel and simple biomarker for assessing disease progression in BC patients.

摘要

髓系来源的抑制细胞(MDSCs)是具有高度免疫抑制作用的髓系细胞,在癌症患者中表达增加;然而,其产生和功能的分子机制尚不清楚。虽然粒细胞性MDSCs与乳腺癌(BC)患者的总体生存率低相关,但单核细胞性(Mo)-MDSCs的存在及其相关性尚不清楚。在此,我们首次报道BC患者中Mo-MDSCs产生趋化因子和趋化因子受体增加。在疾病进展过程中,具有典型细胞表面表型(人类白细胞抗原-D相关[HLA-DR]CD11b CD33 CD14)的Mo-MDSCs明显增多。此外,浸润性BC患者Mo-MDSCs上趋化因子受体的表达水平最高。此外,健康对照(HC)和BC患者的Mo-MDSCs之间存在不同的趋化因子受体表达模式。此外,与HC组相比,浸润性BC组中CD4 T细胞增殖显著降低。然而,导管原位癌(DCIS)组与HC组相比无显著差异。我们的数据表明,监测Mo-MDSCs产生趋化因子和趋化因子受体可能是评估BC患者疾病进展的一种新的简单生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d07/6026688/79ae17c9a6d5/in-18-e23-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验